A decade of percutaneous septal ablation in hypertrophic cardiomyopathy

Circulation Journal

Volumn 75, Issue 1, 2011, Pages 28-37

  Rigopoulos, Angelos G ^a   Seggewiss, Hubert ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Leopoldina Krankenhaus   (Germany)

Author keywords

Cardiomyopathy; Left ventricular hypertrophy; Septal ablation

Indexed keywords

ALCOHOL; HEPARIN;

ABLATION THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; CORONARY ARTERY BLOOD FLOW; DISEASE SEVERITY; FOLLOW UP; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; PATHOPHYSIOLOGY; PATIENT SAFETY; PATIENT SELECTION; PERCUTANEOUS TRANSLUMINAL SEPTAL MYOCARDIAL ABLATION; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME;

BALLOON DILATION; CARDIOMYOPATHY, HYPERTROPHIC; CORONARY ANGIOGRAPHY; ETHANOL; HEART CATHETERIZATION; HEART SEPTUM; HISTORY, 21ST CENTURY; HUMANS; INJECTIONS, INTRA-ARTERIAL; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 78651229020     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0962     Document Type: Article

References (94)

1. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004; 363: 1881-1891.
2. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hyper-trophic cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003; 42: 1687-1713.
3. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outfow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
4. Fifer MA, Vlahakes GJ. Management of symptoms in hypertrophic cardiomyopathy. Circulation 2008; 117: 429-439.
5. Hamada M, Shigematsu Y, Inaba S, Aono J, Ikeda S, Watanabe K, et al. Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction. Circ J 2005; 69: 940-945.
6. Ozaki K, Sakuma I, Mitsuma K, Suzuki T, Tsuchida K, Takahashi K, et al. Effect of cibenzoline and atenolol administration on dynamic left ventricular obstruction due to sigmoid-shaped septum. Circ J 2008; 72: 2087-2091.
7. Maron BJ. Appraisal of dual-chamber pacing therapy in hyper-trophic cardiomyopathy: Too soon for a rush to judgment? J Am Coll Cardiol 1996; 27: 431-432.
8. Maron BJ. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy [Controversies in Cardiovascular Medicine]. Circulation 2007; 116: 196-206; discussion 206.
9. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-214.
10. Seggewiss H. Percutaneous transluminal septal myocardial ablation: A new treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 2000; 21: 704-707.
11. Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Curr Cardiol Rep 2001; 3: 160-166.
12. Maron BJ, Maron MS, Wigle ED, Braunwald E. type=contributor>The &/x&&namegr type=editor&&name&&sname&50-year history&/sname&&/name&&/namegr&, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: From idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54: 191-200.
13. Ommen SR, Nishimura RA. What causes outflow tract obstruction in hypertrophic cardiomyopathy? Heart 2009; 95: 1725-1726.
14. Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomy-opathy with severe outfow obstruction due to anomalous papillary muscle. Circulation 1998; 98: 2505-2508.
15. Angelini P. The "1st septal unit" in hypertrophic obstructive cardiomyopathy: A newly recognized anatomo-functional entity, iden-tifed during recent alcohol septal ablation experience. Tex Heart Inst J 2007; 34: 336-346.
16. Singh M, Edwards WD, Holmes DR Jr, Tajil AJ, Nishimura RA. Anatomy of the frst septal perforating artery: A study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin Proc 2001; 76: 799-802.
17. Rigopoulos A, Sepp R, Palinkas A, Ungi I, Kremastinos DT, Seggewiss H. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: Collateral vessel communication between septal branches. Int J Cardiol 2006; 113: e67-e69.
18. Ross J Jr, Braunwald E, Gault JH, Mason DT, Morrow AG. The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. Circulation 1966; 34: 558-578.
19. Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability of left ventricular outfow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation 1998; 97: 461-466.
20. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy: Clinical spectrum and treatment. Circulation 1995; 92: 1680-1692.
21. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outfow tract obstruction. Circulation 2006; 114: 2232-2239.
22. Brockenbrough EC, Braunwald E, Morrow AG. A hemodynamic technic for the detection of hypertrophic subaortic stenosis. Circulation 1961; 23: 189-194.
23. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-655.
24. Kubo T, Kitaoka H, Okawa M, Hirota T, Hayato K, Yamasaki N, et al. Clinical impact of atrial fbrillation in patients with hypertro-phic cardiomyopathy: Results from Kochi RYOMA Study. Circ J 2009; 73: 1599-1605.
25. Autore C, Bernabo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertro-phic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005; 45: 1076-1080.
26. Elliott P, Gimeno J, Tome M, McKenna W. Left ventricular outfow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur Heart J 2006; 27: 3073; author reply 3073-3074.
27. Sigwart U, Grbic M, Essinger A, Rivier J. L'effect aigu d'une occlusion coronarienne par ballonet de la dilatation transluminale. Schweiz Med Wochenschr 1982; 45: 1631 (in French).
28. Come PC, Riley MF. Hypertrophic cardiomyopathy: Disappearance of auscultatory, carotid pulse, and echocardiographic manifestations of obstruction following myocardial infarction. Chest 1982; 82: 451-454.
29. Brugada P, de Swart H, Smeets JL, Wellens HJ. Transcoronary chemical ablation of ventricular tachycardia. Circulation 1989; 79: 475-482.
30. Kuhn H, Gietzen F, Leuner C, Gerenkamp T. Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: Studies to develop a new catheter-based concept of treatment. Eur Heart J 1997; 18: 846-851.
31. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomy-opathy: Results with respect to intraprocedural myocardial contrast echocardiography. Circulation 1998; 98: 2415-2421.
32. Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 2007; 96: 856-863.
33. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of alcohol septal ablation for obstructive hyper-trophic cardiomyopathy. Circulation 2008; 118: 131-139.
34. Welge D, Seggewiss H, Fassbender D, Schmidt HK, Horstkotte D, Faber L. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Dtsch Med Wochenschr 2008; 133: 1949-1954 (in German).
35. Fernandes VL, Nielsen C, Nagueh SF, Herrin AE, Slifka C, Franklin J, et al. Follow-up of alcohol septal ablation for symptomatic hyper-trophic obstructive cardiomyopathy: The Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardio-vasc Interv 2008; 1: 561-570.
36. Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, et al. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): A 10 year experience. Clin Res Cardiol 2008; 97: 234-243.
37. Kwon DH, Kapadia SR, Tuzcu EM, Halley CM, Gorodeski EZ, Curtin RJ, et al. Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. JACC Cardiovasc Interv 2008; 1: 432-438.
38. Lyne JC, Kilpatrick T, Duncan A, Knight CJ, Sigwart U, Fox KM. Long-term follow-up of the frst patients to undergo transcatheter alcohol septal ablation. Cardiology 2010; 116: 168-173.
39. Faber L, Seggewiss H, Fassbender D, Strick S, Gleichmann U. Guiding of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy by myocardial contrast echocardiography. J Interv Cardiol 1998; 11: 443-448.
40. Veselka J, Duchonova R, Palenickova J, Zemanek D, Tiserova M, Linhartova K, et al. Impact of ethanol dosing on the long-term outcome of alcohol septal ablation for obstructive hypertrophic cardio-myopathy: A single-center prospective, and randomized study. Circ J 2006; 70: 1550-1552.
41. Ruzyłło W, Chojnowska L, Demkow M, Witkowski A, Kusmierczyk-Droszcz B, Piotrowski W, et al. Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardio-myopathy. Eur Heart J 2000; 21: 770-777.
42. Rigopoulos AG, Panou F, Kremastinos DT, Seggewiss H. Alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Hellenic J Cardiol 2009; 50: 511-522.
43. Lever HM. Selection of hypertrophic cardiomyopathy patients for myectomy or alcohol septal ablation. Anadolu Kardiyol Derg 2006; 6(Suppl 2): 27-30.
44. Seggewiss H, Faber L, Meyners W, Bogunovic N, Odenthal HJ, Gleichmann U. Simultaneous percutaneous treatment in hypertro-phic obstructive cardiomyopathy and coronary artery disease: A case report. Cathet Cardiovasc Diagn 1998; 44: 65-69.
45. Baggish AL, Smith RN, Palacios I, Vlahakes GJ, Yoerger DM, Picard MH, et al. Pathological effects of alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Heart 2006; 92: 1773-1778.
46. Yoerger DM, Picard MH, Palacios IF, Vlahakes GJ, Lowry PA, Fifer MA. Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2006; 97: 1511-1514.
47. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 1998; 31: 252-258.
48. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999; 47: 94-100.
49. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up. J Am Coll Cardiol 2000; 36: 852-855.
50. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardio-myopathy. Circulation 2001; 103: 1492-1496.
51. Aqel RA, Hage FG, Zohgbi GJ, Tabereaux PB, Lawson D, Heo J, et al. Serial evaluations of myocardial infarct size after alcohol septal ablation in hypertrophic cardiomyopathy and effects of the changes on clinical status and left ventricular outfow pressure gradients. Am J Cardiol 2008; 101: 1328-1333.
52. van Dockum WG, ten Cate FJ, ten Berg JM, Beek AM, Twisk JW, Vos J, et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopa-thy: Evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 2004; 43: 27-34.
53. Schulz-Menger J, Strohm O, Waigand J, Uhlich F, Dietz R, Friedrich MG. The value of magnetic resonance imaging of the left ventricular outfow tract in patients with hypertrophic obstructive cardio-myopathy after septal artery embolization. Circulation 2000; 101: 1764-1766.
54. Sitges M, Qin JX, Lever HM, Bauer F, Drinko JK, Agler DA, et al. Evaluation of left ventricular outflow tract area after septal reduction in obstructive hypertrophic cardiomyopathy: A real-time 3-dimen-sional echocardiographic study. Am Heart J 2005; 150: 852-858.
55. van Dockum WG, Beek AM, ten Cate FJ, ten Berg JM, Bondarenko O, Gotte MJ, et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2005; 111: 2503-2508.
56. Curtius JM, Stoecker J, Loesse B, Welslau R, Scholz D. Changes of the degree of hypertrophy in hypertrophic obstructive cardio-myopathy under medical and surgical treatment. Cardiology 1989; 76: 255-263.
57. Jaber WA, Yang EH, Nishimura RA, Sorajja P, Rihal CS, Elesber A, et al. Immediate improvement in coronary fow reserve after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Heart 2009; 95: 564-569.
58. van Dockum WG, Knaapen P, Hofman MB, Kuijer JP, ten Cate FJ, ten Berg JM, et al. Impact of alcohol septal ablation on left anterior descending coronary artery blood flow in hypertrophic obstructive cardiomyopathy. Int J Cardiovasc Imaging 2009; 25: 511-518.
59. Pedone C, Biagini E, Galema TW, Vletter WB, ten Cate FJ. Myo-cardial perfusion after percutaneous transluminal septal myocardial ablation as assessed by myocardial contrast echocardiography in patients with hypertrophic obstructive cardiomyopathy. J Am Soc Echocardiogr 2006; 19: 982-986.
60. Soliman OI, Geleijnse ML, Michels M, Dijkmans PA, Nemes A, van Dalen BM, et al. Effect of successful alcohol septal ablation on microvascular function in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol 2008; 101: 1321-1327.
61. Steendijk P, Meliga E, Valgimigli M, Ten Cate FJ, Serruys PW. Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy. Heart 2008; 94: 1318-1322.
62. Meliga E, Steendijk P, Valgimigli M, ten Cate FJ, Serruys PW. Effects of percutaneous transluminal septal myocardial ablation for obstructive hypertrophic cardiomyopathy on systolic and diastolic left ventricular function assessed by pressure-volume loops. Am J Cardiol 2008; 101: 1179-1184.
63. Jassal DS, Neilan TG, Fifer MA, Palacios IF, Lowry PA, Vlahakes GJ, et al. Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J 2006; 27: 1805-1810.
64. Hage FG, Karakus G, Luke WD Jr, Suwanjutah T, Nanda NC, Aqel RA. Effect of alcohol-induced septal ablation on left atrial volume and ejection fraction assessed by real time three-dimensional trans-thoracic echocardiography in patients with hypertrophic cardiomy-opathy. Echocardiography 2008; 25: 784-789.
65. Kazmierczak J, Kornacewicz-Jach Z, Kisly M, Gil R, Wojtarowicz A. Electrocardiographic changes after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Heart 1998; 80: 257-262.
66. Talreja DR, Nishimura RA, Edwards WD, Valeti US, Ommen SR, Tajik AJ, et al. Alcohol septal ablation versus surgical septal myec-tomy: Comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol 2004; 44: 2329-2332.
67. Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hyper-trophic obstructive cardiomyopathy: A systematic review of published studies. J Interv Cardiol 2006; 19: 319-327.
68. Knight C, Sigwart U. Non-surgical ablation of the ventricular septum for the treatment of hypertrophic cardiomyopathy. Heart 1996; 76: 92.
69. Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998; 98: 1750-1755.
70. Gietzen FH, Leuner CJ, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, et al. Acute and long-term results after trans-coronary ablation of septal hypertrophy (TASH): Catheter inter-ventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 1999; 20: 1342-1354.
71. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outfow obstruction only under provocable conditions. Circulation 2002; 106: 454-459.
72. Faber L, Seggewiss H, Welge D, Fassbender D, Ziemssen P, Schmidt HK, et al. Predicting the risk of atrioventricular conduction lesions after percutaneous septal ablation for obstructive hypertro-phic cardiomyopathy. Z Kardiol 2003; 92: 39-47 (in German).
73. Faber L, Seggewiss H, Welge D, Fassbender D, Schmidt HK, Gleichmann U, et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiogr 2004; 5: 347-355.
74. Veselka J, Prochazkova S, Duchonova R, Bolomova-Homolova I, Palenickova J, Tesar D, et al. Alcohol septal ablation for hyper-trophic obstructive cardiomyopathy: Lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical outcome. Catheter Cardiovasc Interv 2004; 63: 231-235.
75. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: Predictors of hemodynamic and clinical response. Clin Res Cardiol 2007; 96: 864-873.
76. Reinhard W, ten Cate FJ, Scholten M, De Laat LE, Vos J. Permanent pacing for complete atrioventricular block after nonsurgical (alcohol) septal reduction in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol 2004; 93: 1064-1066.
77. Chang SM, Nagueh SF, Spencer WH 3rd, Lakkis NM. Complete heart block: Determinants and clinical impact in patients with hyper-trophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol 2003; 42: 296-300.
78. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. Percutaneous septal ablation for symptomatic hyper-trophic obstructive cardiomyopathy: Managing the risk of procedure-related AV conduction disturbances. Int J Cardiol 2007; 119: 163-167.
79. Fifer MA. Most fully informed patients choose septal ablation over septal myectomy [Controversies in Cardiovascular Medicine]. Circulation 2007; 116: 207-216; discussion 216.
80. Antolinos Perez MJ, de la Morena Valenzuela G, Gimeno Blanes JR, Cerdan Sanchez Mdel C, Hurtado Martinez JA, Valdes Chavarri M. Balloon rupture and alcohol leakage into the left anterior descending coronary artery during percutaneous septal ablation for hypertrophic obstructive cardiomyopathy. Rev Esp Cardiol 2005; 58: 872-874 (in Spanish).
81. Kimmelstiel CD, Maron BJ. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2004; 109: 452-456.
82. Maron BJ. Surgery for hypertrophic obstructive cardiomyopathy: Alive and quite well. Circulation 2005; 111: 2016-2018.
83. Seggewiss H, Faber L, Ziemssen P. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Cardiol Rev 1999; 7: 316-323.
84. Boltwood CM Jr, Chien W, Ports T. Ventricular tachycardia complicating alcohol septal ablation. N Engl J Med 2004; 351: 1914-1915.
85. Antoun P, El Masry H, Breall JA. Sudden cardiac death complicating alcohol septal ablation: A case report and review of literature. Catheter Cardiovasc Interv 2009; 73: 956-959.
86. ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: A word of caution. Circ Heart Fail 2010; 3: 362-369.
87. Lawrenz T, Obergassel L, Lieder F, Leuner C, Strunk-Mueller C, Meyer Zu, Vilsendorf D, et al. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 2005; 28: 295-300.
88. Cuoco FA, Spencer WH 3rd, Fernandes VL, Nielsen CD, Nagueh S, Sturdivant JL, et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol 2008; 52: 1718-1723.
89. Noseworthy PA, Rosenberg MA, Fifer MA, Palacios IF, Lowry PA, Ruskin JN, et al. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am J Cardiol 2009; 104: 128-132.
90. Seggewiss H, Faber L. Percutaneous septal ablation for hyper-trophic cardiomyopathy and mid-ventricular obstruction. Eur J Echocardiogr 2000; 1: 277-280.
91. Faber L, Welge D, Hering D, Butz T, Oldenburg O, Seggewiss H, et al. Percutaneous septal ablation after unsuccessful surgical myec-tomy for patients with hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 2008; 97: 899-904.
92. Veselka J, Zemanek D, Tomasov P, Homolova S, Adlova R, Tesar D. Complications of low-dose, echo-guided alcohol septal ablation. Catheter Cardiovasc Interv 2010; 75: 546-550.
93. Kuhn H, Gietzen FH, Leuner C, Schafers M, Schober O, Strunk-Muller C, et al. Transcoronary ablation of septal hypertrophy (TASH): A new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 2000; 89(Suppl 4): IV41-IV54.
94. Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, et al. Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: 846-853.